Intracellular calcium modulators for cardiac muscle in pathological conditions

Japanese Heart Journal

Volumn 37, Issue 1, 1996, Pages 1-17

  Ishide, Nobumasa ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Aftercontraction; Calcium overload; Dantrolene; Digitalis intoxication; Phenytoin; Ryanodine; Sarcoplasmic reticulum; Triggered activity

Indexed keywords

CAFFEINE; CALCIUM ION; DANTROLENE; FLUNARIZINE; MAGNESIUM ION; N [1 [4 (4 FLUOROPHENOXY)BUTYL] 4 PIPERIDINYL] N METHYL 2 BENZOTHIAZOLAMINE; PHENYTOIN; RYANODINE;

CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CALCIUM TRANSPORT; HEART ARRHYTHMIA; HEART MUSCLE; HEART MUSCLE CONTRACTILITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SARCOPLASMIC RETICULUM;

EID: 0029898098     PISSN: 00214868     EISSN: None     Source Type: Journal    
DOI: 10.1536/ihj.37.1     Document Type: Review

References (80)

1. Bers DM. Excitation-contraction coupling and cardiac contractile force. Dordrecht, Kluwer Academic Publishers; 1991.
2. Eisner DA, Lederer WJ. Na-Ca exchange: Stochiometry and Electrogenicity. Am J Physiol 1985; 248: C189-202.
3. Stern MD. Theory of excitation-contraction coupling in cardiac muscle. Biophys J 1992; 63: 497-517.
4. Lopez-Lopez JR, Shacklock PS, Balke CW, Wier WG. Local calcium transients triggered by single L-type calcium currents in cardiac cells. Science 1995; 268: 1042-45.
5. Cannell MB, Cheng H, Lederer WJ. The control of calcium release in heart muscle. Science 1995; 268: 1045-9.
6. Parratt JR, editor. Control and manipulation of calcium movement. New York: Raven Press; 1985.
7. Langer GA, editor. Calcium and the Heart. Raven Press, New York, 1990.
8. Stern MD, Capogrossi MC, Lakatta EG. Spontaneous calcium release from the sarcoplasmic reticulum in myocardial cells: mechanisms and consequences. Cell Calcium 1988; 9: 247-56.
9. 2+ release in the heart. Cardiovasc Res 1992; 26: 193-214.
10. Takamatsu T, Wier WG. Calcium waves in mammalian heart: Quantification of origin, magnitude, waveform, and velocity. FASEB J 1990; 4: 1519-25.
11. Endo M, Tanaka M, Ogawa Y. Calcium induced release of calcium from the sarcoplasmic reticulum of skinned skeletal muscle fibres. Nature 1970; 228: 34-6.
12. Miura M, Ishide N, Sakurai M, Shinozaki T, Takishima T. Interactions between calcium waves and action potential-induced calcium transients in guinea pig myocytes. Heart Vessels 1994; 9: 79-86.
13. 2+]i in single heart cells revealed by Fura-2. Science 1987, 235: 325-8.
14. Ishide N, Urayama T, Inoue K, Komaru T, Takishima T. Propagation and collision characteristics of calcium waves in rat myocytes. Am J Physiol 1990; 259: H940-50.
15. 2+ in mammalian cardiac muscle. Nature 1983; 304: 735-8.
16. Rieser G, Sabbadini R, Paolini P, Fry M, Inesi G. Sarcomere motion in isolated cardiac cells. Am J Physiol 1979; 236: C70-7.
17. Capogrossi MC, Lakatta EG. Frequency modulation and synchronization of spontaneous oscillations in cardiac cell. Am J Physiol 1985; 248: H412-8.
18. Ishide N, Watanabe H, Takishima T. Effects of calcium paradox on spontaneous sarcomere motions in isolated rat cardiac muscle. J Mol Cell Cardiol 1984; 16. 421-6.
19. Lappe DL, Lakatta EG. Intensity fluctuation spectroscopy monitors contractile activation in 'resting' cardiac muscle. Science 1980; 207: 1369-71.
20. Glitsch HG, Pott L. Spontaneous tension oscillations in guinea-pig atrial trabeculae. Pflugers Arch 1975; 358: 11-25.
21. Lee HC, Mohabir R, Smith N, Franz MR, Clusin WT. Effect of ischemia on calcium-dependent fluorescence transients in rabbit heart containing Indo-1. Circulation 1988; 78: 1047-59.
22. 2+ oscillations in isolated hearts. Am J Physiol 1989; 257: H665-73.
23. Shinozaki T, Ishide N, Miura M, Takishima T. The source of epifluorescence in isolated perfused heart loaded with fura 2-AM or indo 1-AM. Heart Vessels 1993; 8: 79-84.
24. 2+]i overload in rat ventricular muscle. Am J Physiol 1987; 253: H737-44.
25. Cranefield PF, Aronson RS. Cardiac arrhythmias, Mount Kisco: Futura; 1988: 4.
26. 2+ concentration. Heart Vessels (in press).
27. Miura M, Ishide N, Oda H, Sakurai M, Shinozaki T, Takishima T. Spatial features of calcium transients during early and delayed after depolarizations. Am J Physiol 1993; 265: H439-44.
28. Eisner DA, Lederer WJ, Sheu SS. The role of intracellular sodium activity in the anti-arrhythmic action of local anesthetics in sheep Purkinje fibres. J Physiol 1983; 340: 239-57.
29. Sheu SS, Lederer WJ. Lidocaine's negative inotropic and antiarrhythmic actions. Dependence on shortening of action potential duration and reduction of intracellular sodium activity. Circ Res 1985; 57: 578-90.
30. Carafoli E. Sarcolemmal calcium pump. In: Langer GA, editor. Calcium and the Heart, New York: Raven Press, 1990; 109-26.
31. Palade P, Dettbarn C, Brunder D, Stein P, Hals G. Pharmacology of calcium release from sarcoplasmic reticulum. J Bioenerg Biomemb 1989; 21: 295-320.
32. Tzivoni D, Keren A, Cohen AM. Magnesium therapy for torsade de pointes. Am J Cardiol 1984; 53: 528-31.
33. Surawicz B. Electrophysiologic substrate of torsade de pointes: Dispersion of repolarization or early after depolarizations? J Am Coll Cardiol 1989; 14: 172-84.
34. Szekely P, Wynne NA. The effects of magnesium on cardiac arrhythmias caused by digitalis. Clin Sci 1951; 10: 241-7.
35. Aomine M, Tatsukawa Y, Ehara T. Antiarrhythmic effects of magnesium on single ventricular myocytes. Kokyu-to-junkan 1992; 40: 677-83 (in Japanese with English abstract).
36. 2+ and phosphorylation. Science 1995; 267: 1997-2000.
37. 2+ release channel of sarcoplasmic reticulum. J Biol Chem 1986; 261: 6300-6.
38. Lakatta EG, Capogrossi MC, Kort AA, Stern MD. Spontaneous myocardial calcium oscillations: Overview with emphasis on ryanodine and caffeine. Fed Proc 1985; 44: 2977-83.
39. Hajdu S, Leonard E. Action of ryanodine on mammalian cardiac muscle. Effects on contractility and reversal of digitalis-induced ventricular arrhythmias. Circ Res 1961, 9: 1291-8.
40. Kahn M, Shiffmann I, Kuhn LA, Jacobsen TE. Effects of ryanodine in normal dogs and in those with digitalis-induced arrythmias. Am J Cardiol 1964; 14: 658-68.
41. Golovina VA, Zakharov SI, Bogdanov KY, Rosenshtraukh LV. Analysis of antiarrhythmic effect of ryanodine in guinea-pigs. J Mol Cell Cardiol 1988; 20: 303-31.
42. Thandroyen FT, McCarthy J, Burton KP, Opie LH. Ryanodine and caffeine prevent ventricular arrhythmias during acute myocardial ischemia and reperfusion in rat heart. Circ Res 1988; 62: 306-14.
43. Ishide N, Watanabe H, Takishima T. Effects of high-K, low-Na, diltiazem, caffeine and Ba on spontaneous fluctuating contractile activities in rat cardiac muscle. Tohoku J Exp Med 1984; 144: 331-41.
44. Britt BA. Dantrolene. Can Anesth Soc J 1984; 31: 61-75.
45. Ward A, Chaffman O, Sorkin EM. Dantrolene: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant symptom and an update of its use in muscle spasticity. Drugs 1986; 32: 130-68.
46. Ellis KO, Castellion AW, Honkomp LJ, Wessels FL, Carpenter JF, Halliday RP. Dantrolene, a direct acting skeletal muscle relaxant. J Pharm Sci 1973; 62: 948-51.
47. van Winkle WB. Calcium release from skeletal muscle sarcoplasmic reticulum: Site of action of Dantrolene sodium? Science 1976; 193: 1130-31.
48. Eilis KO, Butterfield JL, Wessels FL, Carpenter JF. A comparison of skeletal, cardiac, and smooth muscle actions of dantrolene sodium - a skeletal muscle relaxant. Arch Int Pharmacodyn 1976; 224: 118-32.
49. Gollan F, McDermott J. Effect of the skeletal muscle relaxant dantrolene sodium on the isolated perfused heart. Proc Soc Exp Biol Med 1979; 160: 42-5.
50. Meyer WJ, Wesseling H, Agoston S. The effects of dantrolene sodium on cardiac and skeletal muscle in rats. Europ J Pharmacol 1976; 39: 127-31.
51. Plizga A, Holl JE. Myocardial depression associated with effective refractory period prolongation after pentobarbital and procainamide but not after dantrolene. Res Comm Chem Pathol Pharmac 1980; 28: 13-26 .
52. Hiraoka M, Kinoshita H, Kawano S. Action of dantrolene sodium on electrical and mechanical activity of guinea-pig ventricular muscles. Jpn J Physiol 1985; 35: 123-38.
53. Salata JJ, Wasserstrom JA, Jalife J. Dantrolene sodium: Effects on isolated cardiac tissues. J Mol Cell Cardiol 1983; 15: 233-43.
54. Meszaros J, Kecskemeti V, Szegi J. Effect of dantrolene sodium on the mechanical and electrical properties of guinea-pig ventricular myocardium. Arch Int Pharmacodyn 1982; 255: 256-68.
55. Herman R, Mayer N, Mecomber SA. Clinical pharmacology of dantrolene sodium. Am J Phys Med 1972; 51: 296-311.
56. 2+ overloaded rat cardiac muscle. Circulation 1993; 88: I-372 (abstract).
57. Wit AL, Rosen MR, Hoffman BF. Electrophysiology and pharmacology of cardiac arrythmias. VIII. Cardiac effects of diphenylhydantoin. B. Am Heart J 1975; 90: 397-404.
58. Scheuer T, Kass RS. Phenytoin reduces calcium current in the cardiac Purkinje fiber. Circ Res 1983; 53: 16-23.
59. Yatani A, Hamilton SL, Brown AM. Diphenylhydantoin blocks cardiac calcium channels and binds to the dihydropyridine receptor. Circ Res 1986; 59: 356-61.
60. Tegtmeier F, Wilhelm D, Frankow C, Thone F, Vandeplassche L, Peters T. Effect of R56865 and phenytoin on mechanical, biochemical, and morphologic changes during ouabain intoxication in isolated perfused rabbit heart. J Cardiovasc Pharm 1992; 20: 421-8.
61. Kort AA, Lakatta EG. Laser spectroscopy identifies contrasting mechanisms of drugs known to suppress arrhythmias associated with spontaneous myocardial Ca oscillations. Clin Res 1985; 33: 519A (abstract).
62. Koch P, Wilffert B, Peters T. R56865: a new anti-ischemic principle. Cardiovascular Drug Rev 1990; 8: 238-54.
63. ver Donk, Borgers M, Verdonck F. Inhibition of sodium and calcium overload pathology in the myocardium: A new cytoprotective principle. Cardiovasc Res 1993; 27: 349-57.
64. Vollmer B, Meuter C, Janssen PAJ. R56865 prevents electrical and mechanical signs of ouabain intoxication in guinea-pig papillary muscle. Eur J Pharm 1987; 142: 137-40.
65. Leyssens A, Carmeliet E. Block of the transient inward current by R56865 in guinea-pig ventricular myocytes. Eur J Pharm 1991; 196: 43-51.
66. Daniels MCG, ter Keurs HEDJ. Suppressive effect of R56865 on triggered propagated contractions and triggered arrythmias in rat cardiac trabeculae. J Cardiovasc Pharm 1992; 20: 187-96.
67. Ichikawa H, Hearse DJ, Coetzee W. Effects of R-56865 on transient inward current, Na-Ca exchange, and Ca release from SR in cardiac myocytes. Am J Physiol 1994; 266: H511-H520.
68. McGarry SJ, Scheufler E, Williams AJ. Effect of R56865 on cardiac sarcoplasmic reticulum function and its role as an antagonist of digoxin at the sarcoplasmic reticulum calcium release channel. Brit J Pharm 1995; 114: 231-7.
69. Hester RK, Shibata S. KT-362 related effects on intracellular calcium release and associated clinical potential: arrhythmias, myocardial ischemia, and hypertension. Cardiovasc Drugs Ther 990; 4: 1345-54.
70. Pelc LR, Faber NE, Warltier DC, Gross GJ. Reduction of myocardial ischemia-reperfusion injury by KT-362, a new intracellular calcium antagonist in anesthetized dogs. J Cardiovasc Pharmacol 1989; 13: 586-93.
71. Hashimoto K, Watanabe K, Mochizuki S, Tomiyama A. Effects of KT-362, a new Na and Ca flux and Ca release inhibitor, on canine ventricular arrythmias. Jpn J Pharmacol 1989; 51: 475-82.
72. Kodama I, Shibata S. Effects of KT-362, a new antiarrhythmic agent with vasodilating action on intracellular calcium mobilization of atrial muscle. J Pharmacol Exp Ther 1991; 258: 332-8.
73. Cheng YN, Aomine M, Kiyosue T, Arita M. Effects of KT-362, a putative intracellular calcium antagonist, on delayed afterdepolarization, triggered activity and aftercontraction in guinea pig ventricular myocardium (abstract). In: Hashiba K., ed. International Symposium on QT Prolongation and Ventricular Arrhythmias, Nagasaki: Nagasaki Univ. 1991: p7-2.
74. Shibata S, Wakabayashi S, Satake N, Hester RK, Ueda S, Tomiyama A. Mode of vasorelaxing action of 5-[3-[[2-(3,4-dimethioxyphenyl)-ethyl] amino]-1-oxopropyl]-2,3,4,5- tetrahydro-1,5-benzothiazepine fumarate (KT-362), a new intracellular calcium antagonist. J Pharmacol Exp Ther 1987: 240: 16-22.
75. 2+ level in the rat aorta. Br J Pharmacol 1991; 102: 174-8.
76. Holmes B, Brogden RN, Heel RC, Speight TM, Avery GS. Flunarizine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs 1984; 27: 6-44.
77. Vos MA, Gorgels APM, Leunissen JDM, Wellens HJJ. Flunarizine allows differentiation between mechanisms of arrhythmias in the intact heart. Circulation 1990; 81: 343-9.
78. Vos MA, Gorgels APM, Leunissen JDM, van der Nagel T, Halbertsma FJJ, Wellen HJJ. Further observations to confirm the arrhythmia mechanism-specific effects of flunarizine. J Cardiovasc Pharm 1992; 19: 682-90.
79. 2+ release from isolated sarcoplasmic reticulum. Biochem Pharm 1993; 45: 1301-9.
80. Montastruc JL, Llau ME, Rascol O, Senard JM. Drug-induced Parkinsonism: a review. Fundam Clin Pharmacol 1994; 8: 293-306.